BBI Solutions (BBI) has vastly increased its antibodies range across a wide variety of disease areas including bone metabolism, cardiac, growth factors, thyroid, and sepsis. This range extension has been in response to growing demand in the IVD market.
The IVD industry is estimated to grow to $75.1 billion by 2020, at a CAGR of 5.8% from 2015 to 2020. BBI has already noticed an increased demand for antibodies and have expanded their antibodies range in response to customer enquiries.
Some of the products already proving to be popular in the new range are Vitamin D2 and D3, Procalcitonin and NT-proBNP.
The Vitamin D2 and D3 products will help with the diagnosis and monitoring of Vitamin D deficiencies. Deficiencies in Vitamin D can be a risk factor for a number of medical conditions including, osteomalacia, rickets and osteoporosis.